252 related articles for article (PubMed ID: 26397968)
21. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
Al-Baghdadi O; Ewies AA
Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
[TBL] [Abstract][Full Text] [Related]
22. The urogenital system and the menopause.
Calleja-Agius J; Brincat MP
Climacteric; 2015; 18 Suppl 1():18-22. PubMed ID: 26366796
[TBL] [Abstract][Full Text] [Related]
23. What should guide our patient management of vulvovaginal atrophy?
Shapiro M
Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
[TBL] [Abstract][Full Text] [Related]
24. Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats.
Ismail NH; Ibrahim SF; Mokhtar MH; Yahaya A; Zulkefli AF; Ankasha SJ; Osman K
Front Endocrinol (Lausanne); 2023; 14():1031066. PubMed ID: 36923220
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic evaluation of ospemifene.
McCall JL; DeGregorio MW
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):773-9. PubMed ID: 20429673
[TBL] [Abstract][Full Text] [Related]
26. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Pagano T; De Rosa P; Vallone R; Schettini F; Arpino G; De Placido S; Nazzaro G; Locci M; De Placido G
Menopause; 2016 Oct; 23(10):1108-13. PubMed ID: 27648595
[TBL] [Abstract][Full Text] [Related]
27. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.
Nappi RE; Palacios S
Climacteric; 2014 Feb; 17(1):3-9. PubMed ID: 24423885
[TBL] [Abstract][Full Text] [Related]
28. Treatment of the genitourinary syndrome of menopause.
Palacios S; Mejía A; Neyro JL
Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
[TBL] [Abstract][Full Text] [Related]
29. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
30. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.
Krychman M; Graham S; Bernick B; Mirkin S; Kingsberg SA
J Sex Med; 2017 Mar; 14(3):425-433. PubMed ID: 28202319
[TBL] [Abstract][Full Text] [Related]
31. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
32. New developments in the management of vulvovaginal atrophy: a comprehensive overview.
Donders GGG; Donders FHWV
Expert Opin Pharmacother; 2023 Apr; 24(5):599-616. PubMed ID: 36951262
[TBL] [Abstract][Full Text] [Related]
33. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
[TBL] [Abstract][Full Text] [Related]
34. Hormonal Medications for Genitourinary Syndrome of Menopause.
Pinkerton JV; Vaughan MH; Kaunitz AM
Clin Obstet Gynecol; 2024 Mar; 67(1):68-78. PubMed ID: 38032827
[TBL] [Abstract][Full Text] [Related]
35. Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.
Freedman MA
Womens Health (Lond); 2014 Jul; 10(4):445-54. PubMed ID: 25259904
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.
Biehl C; Plotsker O; Mirkin S
Menopause; 2019 Apr; 26(4):431-453. PubMed ID: 30363010
[TBL] [Abstract][Full Text] [Related]
37. Atrophic vaginitis.
Stika CS
Dermatol Ther; 2010; 23(5):514-22. PubMed ID: 20868405
[TBL] [Abstract][Full Text] [Related]
38. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
J Sex Med; 2014 Dec; 11(12):2865-72. PubMed ID: 25155380
[TBL] [Abstract][Full Text] [Related]
39. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
40. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause.
Cox P; Panay N
Climacteric; 2023 Aug; 26(4):367-372. PubMed ID: 37199295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
